NZ613666A - Process for preparation of a herbal extract - Google Patents
Process for preparation of a herbal extractInfo
- Publication number
- NZ613666A NZ613666A NZ613666A NZ61366612A NZ613666A NZ 613666 A NZ613666 A NZ 613666A NZ 613666 A NZ613666 A NZ 613666A NZ 61366612 A NZ61366612 A NZ 61366612A NZ 613666 A NZ613666 A NZ 613666A
- Authority
- NZ
- New Zealand
- Prior art keywords
- juice
- allowing
- alkali
- acid
- extract
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 33
- 238000002360 preparation method Methods 0.000 title description 17
- 239000003513 alkali Substances 0.000 claims abstract description 19
- 235000009811 Momordica charantia Nutrition 0.000 claims abstract description 18
- 240000004175 Momordica charantia Species 0.000 claims abstract description 18
- 150000007524 organic acids Chemical class 0.000 claims abstract description 17
- 230000001264 neutralization Effects 0.000 claims abstract description 15
- 230000005591 charge neutralization Effects 0.000 claims abstract description 12
- 238000006386 neutralization reaction Methods 0.000 claims abstract description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 7
- 238000001035 drying Methods 0.000 claims abstract description 4
- 238000001914 filtration Methods 0.000 claims abstract description 4
- 235000021022 fresh fruits Nutrition 0.000 claims abstract description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 30
- 239000000843 powder Substances 0.000 claims description 29
- 239000002775 capsule Substances 0.000 claims description 20
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 15
- 235000009815 Momordica Nutrition 0.000 claims description 12
- 241000218984 Momordica Species 0.000 claims description 12
- MUBZPKHOEPUJKR-UHFFFAOYSA-N oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 12
- 230000002378 acidificating Effects 0.000 claims description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 239000008187 granular material Substances 0.000 claims description 8
- 239000003826 tablet Substances 0.000 claims description 7
- 239000006187 pill Substances 0.000 claims description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M NaHCO3 Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 4
- 235000006408 oxalic acid Nutrition 0.000 claims description 4
- -1 sachet Substances 0.000 claims description 4
- 235000005979 Citrus limon Nutrition 0.000 claims description 3
- 240000002268 Citrus limon Species 0.000 claims description 3
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 claims description 3
- 229940023488 Pill Drugs 0.000 claims description 3
- 235000011054 acetic acid Nutrition 0.000 claims description 3
- 235000015165 citric acid Nutrition 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 3
- 239000004310 lactic acid Substances 0.000 claims description 3
- 235000014655 lactic acid Nutrition 0.000 claims description 3
- 239000007937 lozenge Substances 0.000 claims description 3
- 235000010603 pastilles Nutrition 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 239000011975 tartaric acid Substances 0.000 claims description 3
- 235000002906 tartaric acid Nutrition 0.000 claims description 3
- 229960001367 tartaric acid Drugs 0.000 claims description 3
- 238000001291 vacuum drying Methods 0.000 claims description 3
- 238000009777 vacuum freeze-drying Methods 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxyl anion Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 2
- 238000001694 spray drying Methods 0.000 claims description 2
- 229920000591 gum Polymers 0.000 claims 1
- 230000003472 neutralizing Effects 0.000 claims 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- 239000011591 potassium Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 235000013399 edible fruits Nutrition 0.000 description 18
- 210000004369 Blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 239000000470 constituent Substances 0.000 description 12
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 11
- 239000008103 glucose Substances 0.000 description 11
- 238000003756 stirring Methods 0.000 description 8
- 206010012601 Diabetes mellitus Diseases 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- 238000007792 addition Methods 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000004140 cleaning Methods 0.000 description 6
- 239000002002 slurry Substances 0.000 description 6
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinylpyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 4
- 229940069328 Povidone Drugs 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 229910002012 Aerosil® Inorganic materials 0.000 description 3
- NEFBYIFKOOEVPA-UHFFFAOYSA-K Dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 3
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 229940038472 dicalcium phosphate Drugs 0.000 description 3
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 3
- 239000000428 dust Substances 0.000 description 3
- 230000002218 hypoglycaemic Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 229940079832 sodium starch glycolate Drugs 0.000 description 3
- 239000008109 sodium starch glycolate Substances 0.000 description 3
- 229920003109 sodium starch glycolate Polymers 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000019640 taste Nutrition 0.000 description 3
- AXCZMVOFGPJBDE-UHFFFAOYSA-L Calcium hydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 2
- 229940112822 Chewing Gum Drugs 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 229960003105 Metformin Drugs 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N Saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 210000003491 Skin Anatomy 0.000 description 2
- 208000001072 Type 2 Diabetes Mellitus Diseases 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000004159 blood analysis Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 235000021152 breakfast Nutrition 0.000 description 2
- 239000000920 calcium hydroxide Substances 0.000 description 2
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000015218 chewing gum Nutrition 0.000 description 2
- 230000001419 dependent Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 229940074774 glycyrrhizinate Drugs 0.000 description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-K glycyrrhizinate(3-) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C([O-])=O)C)(C)CC2)(C)CC1)(C)C)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-K 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000006011 modification reaction Methods 0.000 description 2
- 239000002417 nutraceutical Substances 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000003389 potentiating Effects 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-M stearate Chemical compound CCCCCCCCCCCCCCCCCC([O-])=O QIQXTHQIDYTFRH-UHFFFAOYSA-M 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 210000003423 Ankle Anatomy 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- 241000219104 Cucurbitaceae Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 210000002683 Foot Anatomy 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010051602 Laziness Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010040872 Skin infection Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 235000008322 Trichosanthes cucumerina Nutrition 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K Trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 210000002700 Urine Anatomy 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 230000001058 adult Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003178 anti-diabetic Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000002542 deteriorative Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002708 enhancing Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000004301 light adaptation Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 239000008368 mint flavor Substances 0.000 description 1
- 230000003000 nontoxic Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting Effects 0.000 description 1
- 230000001681 protective Effects 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- 230000036620 skin dryness Effects 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 230000002522 swelling Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 230000002588 toxic Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 239000011778 trisodium citrate Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 200000000019 wound Diseases 0.000 description 1
Abstract
613666 Disclosed is a process for preparing an extract of Momordica charantia comprising the following steps: a) preparing crude juice from crushed and chopped unripe Momordica charantia fresh fruit to which water is added intermittently; b) filtering the crude juice to obtain filtered juice; c) modifying the pH of the juice between 2.5 to 4 pH by adding an organic acid; d) allowing the pH modified juice to stabilise by allowing the pH added filtered juice to stand for 5 to 25-minutes; e) neutralising the stabilised juice with the help of alkali; f) allowing the neutralised juice to stand for a period of 20 to 30 minutes; g) rechecking the pH level of the juice for neutralisation; and h) drying the neutralised juice to obtain dried extract of Momordica charantia. c) modifying the pH of the juice between 2.5 to 4 pH by adding an organic acid; d) allowing the pH modified juice to stabilise by allowing the pH added filtered juice to stand for 5 to 25-minutes; e) neutralising the stabilised juice with the help of alkali; f) allowing the neutralised juice to stand for a period of 20 to 30 minutes; g) rechecking the pH level of the juice for neutralisation; and h) drying the neutralised juice to obtain dried extract of Momordica charantia.
Description
PROCESS FOR PREPARATION OF A HERBAL EXTRACT
FIELD
The present disclosure relates to a process for preparation of a herbal extract
powder.
More particularly, the present disclosure s to a process for preparation of a
herbal extract powder from Momordz'ca charantia.
BACKGROUND
MomordicaecharantiariS'alsO’ca'l'ledrbitter‘m'el'on’or‘b‘itte’r—go—urdflt is a tro—pifil"
and subtropical vine of the family Cucurbitaceae, widely grown in Asia, Africa
and the ean for its edible fruit, which is among the most bitter of all fruits.
There are many ies that differ substantially in the shape and bitterness of the
fruit.
Processes for extraction of the active constituents from s parts Momordica
charantia and the formulations these constituents have been disclosed in Indian
Patent 81887, GB1435664, IN156263, USSO98710, JP3112999, CN1180545,
US6852695, US6831162 IN191582, CN1253734 CN1303698, IN188858,
IN826/DEL/2000, IN768/MUM/2001, CN1418890, IP2005126370,CN1562340,
CN1858223, IP2006314273, CN1709900, 134, 120701,
TW200927139, CN101366806, CN101461514, CN101485429, CN101597389
and CN101637491.
The hitherto reported processes for extraction of the active constituents from
various parts Momordl'ca tz'a suffer from several limitations which include :
use of organic solvents for extraction, use of heat during processing, use of
enzymes during the tion process, use of sophisticated equipments for the
extraction s.
Also, the formulations comprising the Momordica constituents suffer from
numerous short-comings which include lower shelf life, reduction in the potency
and high cost on account of high processing.
There is therefore felt a need for a process for extraction of the active constituents
from Momordica charantia which is simple, cost effective, which does not employ
any harmful c solvents and which enhances the potency of the constituents.
A need is also felt for a formulation.comprisingacti-veconst-ituentsof-Momordica’
charantia which is simple, effective and potent as compared to the existing
product.
OBJECT
Some of the objects of the present sure are as follows:
It is an object of the present disclosure to provide a process for preparation of an
extract of Momordica charantz'a which has a longer shelf life.
It is another object of the present disclosure to provide a process for preparation of
an extract of ica tia which does not employ any enzymes.
It is still another object of the present disclosure to provide a process for
preparation of an t of Momordz'ca charantia which does not employ organic
solvents.
It is yet another object of the present sure to provide a process for
preparation of an extract of Momordica charantia which increases the potency of
the extract.
It is yet another 'of the present disclosure to provide a process for
ation of an extract of ’z'ca charantia wherein the end product is non-
hygroscopic.
SUMMARY
In accordance with the present disclosure there is provided a process for preparing
an extract of Momordica charantz'a comprising_the_followingisteps:7
a) preparing crude juice from crushed and chopped unripe Momordica
charantz'a fresh fruit to which water is added intermittently;
b) filtering the crude juice to obtain filtered juice;
c) modifying the pH of the juice between 2.5 to 4 pH by adding an
organic acid;
(1) allowing the pH modified juice to ize by allowing the pH added
filtered juice to stand for 5 to 25 minutes;
e) lizing the stabilized juice with the help of alkali;
0 allowing the neutralized juice to stand for a period of 20 to 30 minutes;
g) rechecking the pH level of the juice for lization; and
h) drying the neutralized juice to obtain dried extract of Momordica
charantia.
Typically, the organic acid is at least one selected from the group consisting of
citric acid, acetic acid, lactic acid, tartaric acid and oxalic acid.
Typically, the organic acid is citric acid.
Typically, the organic acid is lemon juice.
Typically, the acidic pH is adjusted to a value of 3.8.
Typically, the alkali used for neutralization is at least one alkali selected from the
group consisting of sodium hydroxide, ium hydroxide, calcium ide
and sodium onate.
Typically, the normality of the alkali used for neutralization is in the range of 0.1
Nto4N.
In accordance with the present'disclosure, during the step of neutralization the
alkali is added dropwise in the stabilized acidic juice.
In ance with the present disclosure, the dried extract is obtained by treating
the neutralized juice in at least one manner selected from the group consisting of
spray , vacuum drying and freeze drying to obtain a dried extract of
Momordz'ca chararztia.
There is also provided a ation containing the dried extract of Momordica
charantia prepared in accordance with the present disclosure in a dosage form
selected from the group consisting of powder, granule, capsule, tablet, sachet,
suspension, , pastille, chewing gum, lozenges and pill.
DETAILED DESCRIPTION
In one aspect, the present disclosure provides a process for preparation of a herbal
extract powder from Momordz'ca charantz'a. The first and foremost consideration
beforethe commencement of any herbal extraction process is the selection of the
particular plant part for the purposes of extraction. Accordingly, the first step in
ance of the process with the present disclosure is selection of the raw
material.
In accordance with the process of the t disclosure, fruits are used as the raw
material for the tion process.
lly, green colored unripe fruits are used as the raw material.
Typically, the fruits that are used as the raw material are fresh.
A crude juice is prepared by crushing and ng the fruits with intermittent
addition of water. The crude juice is then subjected to filtration to obtain a green
coloured juice.
A pH modifying agent is added to render the green coloured juice acidic by
adjusting the pH to a predetermined value.
Typically, a mild organic acid is used as the pH modifying agent.
Typically, the organic acid is at least one selected from the group consisting of
citric acid, acetic acid, lactic acid, tartaric acid, oxalic acid and or the like, or the
ations thereof.
In accordance with one embodiment, citric acid is used as the pH modifying agent.
The organic acid used as a pH modifying agent may be obtained from a natural
source. Alternatively, the organic acid may be purely synthetic. In one
embodiment, lemon juice is used as the pH modifying agent. In another
embodiment, citric acid is used as the pH modifying agent.
Typically, the pre-determined pH value is selected from the values selected from
the group consisting of 2.5, 3, 3.5 and 4.
In accordance with one embodiment of the disclosure, the predetermined value of
pH is in the range of about 3.5 to about 4.0.
In accordance with still another embodiment of the present disclosure, the
predetermined value of pH is 3.8.
It is believed that the addition of the organic acids in the clear juice converts the
larger./zc.omplex_pr.oteinsgofifreshgfruits-of—Momordicaecharantiaato-sm'a'll—pepti'de'
fractions, which help in reduction of blood glucose levels in ts.
The acidic juice extract with a predetermined pH is allowed to stabilize for a
period in the range of about 5 min to 25 min, preferably, in the range of about 15 .
to 20 minutes.
The stabilized acidic juice is lized by on of an alkali to obtain a
neutralized juice extract with a pH in the range of about 6.5 to 7.
In accordance with a preferred embodiment of the present disclosure, the pH of the
neutralized juice is about 7.
Typically, in the method step of neutralization of the acidic juice using an alkali,
after the addition of the alkali to the acidic juice, the neutralized juice is kept aside
for a period of about 20 to 30 minutes and the pH is cked. If necessary,
additional alkali is added to ust the pH in a range of about 6.5 to about 7,
preferably about 7.
Typically, the alkali used for the neutralization of the acid juice include but are not
limited to sodium hydroxide, potassium hydroxide, calcium hydroxide, sodium
bicarbonate or the like, or the ations thereof.
lly, the normality of the alkali used for neutralization of the acid juice is in
the range of 0.1N to about 4N.
Typically, the alkali is added in a drop~wise manner in the stabilized acidic juice
for a time period ranging between 5 to 10 minutes.
Neutralizationiofiacidic—juicaensuresethe—prevention-of'furth'er-de‘gradatio’an*
peptides in amino acids. Therefore, the fraction prepared from fresh green unripe
fruits of Momordz‘ca charantia (bitter gourd) in accordance with the process of the
present disclosure is found to be more potent as compared to the juice obtained
from the whole fruit.
Theneutralizedjuiceext-ract thus~obtained—iSedried*by‘atrleastone manner‘selec't’ed
from the group consisting of spray drying, vacuum drying and freeze drying to
obtain a dried extract of Momordica charantia.
The Polypeptide—p, charantin and bitter constituents of Momordica charantia fruits
show anti-diabetic activity.
In accordance with another aspect of the present disclosure, there is provided a
herbal ition that comprises the dried t of Momordz’ca charantia
prepared by the process in accordance with the present disclosure.
Typically, the herbal composition is formulated in a dosage form selected from the
group consisting of powder, granule, capsule, tablet, sachet, suspension, liquid,
pastille, chewing gum, lozenges and pill.
The present disclosure will now be described with the help of ing non-
limiting examples.
Examples
Preparation of Momordica charantia powder
Example 1 — 5 Kg of fresh unripe green fruits along with seeds of Momordica
tia Linn were subjected to, cleaning to remove the dust and other
superfluous particles from the fruits. The cleaned fruits were chopped and grinded
to obtain homologous slurry with the addition of approximately 500 ml of water.
The slurry was then filtered to separate the juice by using the nutch filter. The
juice was then ed with 15% of citric acid under continuous stirring to adjust
therpH to 4.0. Theistirringeofjuiceewascontinuedrfor-30 minutes an'd’a‘gain‘p'H wasi ‘
noted. After stabilization of pH, the pH of acidified juice was then neutralized
with help of 15% sodium hydroxide solution to obtain pH to 7.0. The neutralized
juice was then subjected to continuous stirring for 30 minutes and pH was once
again noted to confirm the pH — 7.0. The juice with neutral pH was then
concentrated under nt vacuum at 700 mm of Hg at temperature 55°C to
ed juice with 18 brix (total solid content). The concentrated juice was dried
using vacuum dryer adjusted at 60°C and reduced re, which gave 176 gm of
the greenish brown coloured free flowing juice powder with characteristic taste
and odour.
Analysis of the juice powder showed following constituents in Table 1.
Table 1.
Constituents .......... % by weight
Proteins .......... 22.85
Bitters .......... 3.32
e 2 - 5 Kg of fresh unripe green fruits along with seeds of Momordica
charantia Linn were subjected to cleaning to remove the dust and other
superfluous particles from the fruits. The cleaned fruits were chopped and grinded
to obtain homologous slurry with the addition of approximately 500 ml of water.
The slurry was then filtered to te the juice by using the high speed
centrifiig‘e. The juice was then acidified with 15% of citric acid under continuous
stirring to adjust the pH to 4.0. The stirring e was continued for 30 minutes
and again pH was noted. After ization of pH, the pH of acidified juice was
then neutralized with help of 15% sodium hydroxide solution to obtain pH to 7.0.
The neutralized juice was then subjected to continuous stirring for 30 minutes and
pH was once again noted to confirm the pH — 7.0. The juice with neutral pH was
then concentrated under constant vacuum at 700 mm of Hg at temperature 55°C to
obtained juice with 16 brix (total solid content). The concentrated juice was dried
using spray dryer at 155°C inlet temperature, 70°C to 80°C outlet temperature,
which gave 159 gm of greenish brown ed free flowing juice powder with
characteristic taste and odour. Analysis of the juice powder showed following
constituents in Table 2.
Table 2.
tuents .......... % by weight
Proteins .......... 22 15
Bitters .... 2 76
e 3 - 5 Kg of fresh unripe green fruits along with seeds of Momordz’ca
charantia Linn were subjected to cleaning to remove the dust and other
superfluous particles from the . The cleaned fruits were chopped andzgrinded.
to obtain homologous slurry with the addition of approximately 500 ml of water.
The slurry was then filtered to separate the juice by using the high speed
centrifuge. The juice was then acidified with 15% of oxalic acid under continuous
stirring to adjust the pH to 4.0. The stirring ofjuice was continued for 30 minutes
and again pH was noted. After stabilization of pH, the pH of acidified juice Was
then neutralized with help of 15% Calcium hydroxide solution to obtain pH to 7.0.
The neutralized juice was then subjected to continuous stirring for 30 minutes and
pH was once again noted to confirm the pH — 7.0. The juice with neutral pH was
then concentrated under constant vacuum at 700 mm of Hg at temperature 55°C to
obtained juice with 18 brix (total solid content). The concentrated juice was dried
using freeze dryer adjusted at -46°C and reduced pressure, which gave 165 gm of
green coloured free flowing juice powder with characteristic taste and odour.
Analysis of the juice powder showed following constituents in Table 3.
Table 3.
Constituents .......... % by weight
Proteins .......... 21.3 3
Bitters .......... 2. 85
Preparation of capsules of Momordica ‘z'a 400 mg.
Example 4 - The juice powder of Momordz'ca charantz'a, microcrystalline cellulose,
aerosi_l,digflcjumphosphateaweresiftedthroughi40—U-Semesh*screen:bl'en'ded‘a’nd’
granulated using an aqueous on of Povidone (PVPK-30). The granules were
then dried at temperature of 60 j: 5° C, sifted through 30 US mesh screen,
lubricated and filled into hard gelatin capsule shells of suitable size.
The capsules had composition as given below in Table 4.
Table 4.
Ingredients .......... Quantity per mg in capsule
Microcrystalline ose ........... 100
Aerosil ........... 3
Dicalcium phosphate ........... 40
Povidone (PVPK-30) ........... 5.5
ium stearate ..... 3
Talc ............ 3
Sodium starch glycolate ............ 15
Example 5 - The juice powder of Momordz'ca charantia, sodium carboxymethyl
cellulose, sodium saccharin, citric acid and sodium glycyrrhizinate were sifted
through 40 US mesh screen, d and granulated. The granules were then dried
at temperature of 60 : 5° C, sifted through 30 US mesh screen filled either in bulk
or in unit dose per pack.
The granules had composition as given below in Table 5.
Table 5.
ients ty in mg
Juice powderof Momordica charantz‘a of example 1 .......... 400
Sodium glycyrrhizinate .......... 10
Sodium citrate .......... 20
Mint flavour (0.1%) .......... 1
Sodium carboxy methyl cellulose .......... 2
Sodium saccharin .......... 1
Preparation of tablets ofMomordica charantia fraction 600 mg.
e 6 - The juice powder of Momordica charantz’a of example 1,
microcrystalline cellulose, aerosil, dicalcium phosphate were sifted through 40 US
mesh screen, blended and granulated using an s on of Povidone
(PVPK-30). The granules were then dried at temperature of 60 : 5° C, sifted
through 30 US mesh screen and lubricated using talc, magnesium stearate and
sodium starch glycolate. The lubricated granules were then compressed using
suitable die and punches and coated.
The tablets had composition as given below in Table 6.
Table 6.
Ingredients .......... Quantity per mg in tablet
Microcrystalline cellulose ........... 100
Aerosil ........... 20
Dicalcium phosphate ........... 50
Povidone (PVPK-30) ........... 10
ium stearate >
..... ...... 5
Talc ............ 5
Sodium starch glycolate ............ 25
y propyl methyl cellulose .......... 8
Titanium dioxide .......... 5
Propylene glycol .......... 3
Anecdotal studies:
1) A subject with uncontrolled type II es was administered three
capsules of Momordica charantz'a ts in ance with the present
disclosure per day containing 400 mg extract per capsule; as obtained from
Example 4.
It was found that blood glucose level of the subject was reduced to
159 mg/dL from its base level — 249 mg/dL during one month of treatment
at aidose of one capsule (400mg) administered three times a day.
2) A test was made of the hypoglycemic effect of the same juice powder of
M charantz’a as employed in Example 4 upon a female patient of 56 years
‘of age and a body weight of 61 kg presenting with non n-dependent
diabetes. The test subject exhibited a daily blood glucose level of
234 mg/dL, with administration of 500 mg of metformin; BID.
The subject continued stration of the same number of pills of
metforrnin per day and commenced ingestion of 3 hard gelatin es
containing 400 mg of Juice powder ofM charantia per capsule as obtained
from example 4 for a period of 90 days. The practiced dosage regimen was
1 e before breakfast and 2 capsules before dinner.
The blood analysis of patient showed dramatic effect where the blood
glucose level of the subject d to 170 mg/dL from its base level —
234 mg/dL during a three month of treatment. During the treatment, the
patient was on_ _a very moderatediet and __she_ wasfiphysically,moderately
active.
3) A test was made of the hypoglycemic effect of the same juice powder of
M charantia as employed in Example 4 upon a non insulin-dependent
uncontrolled diabetic male of 61 years of age and a body weight of 67 kg.
The t had long history of diabetes and was on oral medication from
more than 5 years. The test subject exhibited a daily blood glucose level of
261 mg/dL, with administration of 500 mg of metformin; three tablets per
day.
The subject continued administration of the same number of pills of
metforrnin per day and commenced ingestion of 3 hard gelatin capsules
containing 400 mg of Juice powder ofM charam‘ia per capsule as obtained
from example 4 for a period of 90 days. The practiced dosage regimen was
1 capsule before breakfast and 2 capsules before dinner.
The blood analysis of the patient showed ic effect where the blood
glucose level of the subject reduced to 159 mg/dL from its base level — 261
mg/dL during a three month of ent.
492A2malegsubject~ofi62~yearsiwithiuncontrolied-maturity'onsetrd'iabetW
administered 3 capsules of commercially available ica charantia
t per day containing 400 mg of commercial powder per capsule.
It was found that after a period of one month blood glucose level of the
subject reduced from a base level of 249 mg/dL to 199 mg/dL consistently.
Thereafter under the same conditions, the t was administered one
capsule as per example 4, three times a day. After one month treatment, the
blood glucose level of the subject reduced to 159 mg/dL.
) A female subject of 70 years with uncontrolled maturity onset diabetes was
administered 3 capsules of commercially available Momordica charantia
extract per day containing 400 mg of commercial powder per capsule.
It was found that after a period of one month, the blood glucose level of the
t reduced from a base level of 265 mg/dL to 215 mg/dL consistently.
Thereafter under the same conditions, the subject was administered one
capsule as per example 4, three times a day. After one month treatment, the
blood glucose level of the subject reduced to 145 mg/dL.
Safeg profile
No toxic s or side effects were ascertained in the testings mentioned above.
The physical status of examined persons showed no sign of any harmful reaction
to treatment. The dosage regimen as well as treatment were patient friendly and
well tolerated by diabetics.
Other Benefits:
Besides controlling the blood/urine sugar level the nutraceutical t(s)
provide additional s in diabetes related human health problems like
reduction in fatigue, weakness, drowsiness, numbing , nt urination,
unusual thirst and hunger, weight loss, swellings on legs/ankles, burning sensation
on feet, palms, relief in skin itching, skin dryness, black patches on skin,
hypertension, increase in sleep comfort, energetic feeling, improvement in
laziness, blurred vision, nt skin infections and slow g of wounds and
sores.
A 20-35% reduction in blood glucose doses was also observed after 12 weeks in
noninsulin-dependent diabetes mellitus (NTDDM) adult ics and can be also
used as adjuvant therapy along with oral treatments.
The present disclosure thus provides the specific ition of Momordica
charantz’a juice powder, the process for the preparation of juice powder and the
medicinal benefits of the same.
Technical advancement: The process for preparation of Momordz'ca tia
juice powder and the ation sized in accordance with the present
disclosure has the following non—limited advancements:
- The present disclosure provides a process for the preparation of a nutraceutical
food supplement for diabetics without deteriorating the nutritional and
pharmaceutical properties of the natural composition like enrichment of
proteins and bitters that are responsible for hypoglycemic activity.
- The process for the preparation of Momordica charantia juice powder in
-accordanc—eiw-ithithe*presentfdisclosure7iS’simple-and—cost—effectivei
- The process for the preparation of Momordica charantz'a juice powder in
accordance with the present disclosure is safe as it does not involve use of any
harmful solvents.
- The Momordz'ca charantia juice powder ed in ance with the
t disclosure is comparatively more effective against diabetes.
- The Momordica charantia juice powder prepared in accordance with the
present disclosure is a natural food which is non toxic, easy to digest with
optimum nutrition, health protective and promotive ties.
Throughout this specification the word ‘6comprise”, or variations such as
“comprises” or “comprising”, will be understood to imply the inclusion of a stated
element, integer or step, or group of elements, integers or steps, but not the
exclusion of any other element, integer or step, or group of elements, integers or
steps.
The use of the expression “at least” or “at least one” suggests the use of one or
more elements or ingredients or quantities, as the use may be in the embodiment
of the ion to achieve one or more of the desired objects or results.
Any discussion of documents, acts, materials, devices, articles or the like that has
been included in this specification is solely for the purpose of providing a context
for the ion. It is not to be taken as an admission that any or all of these
matters form part of the prior art base or were common general knowledge in the
field relevant to the invention as it existed anywhere before the priority date of this
application.
The numerical values given for various physical parameters, dimensions and
quantities are only approximate values and it is envisaged that the values higher
than the cal value assigned to the physical parameters, dimensions and
ties fall within the scope of the invention andthe claims unless there is a
statement in the specification to the contrary.
The foregoing description of the specific ments will so fully reveal the
general nature of the embodiments herein that others can, by applying current
knowledge, readily modify and/or adapt for various applications such specific
embodiments without departing from the generic concept, and, ore, such
adaptations and modifications should and are ed to be comprehended within
the meaning and range of equivalents of the disclosed ments. It is to be
understood that the phraseology or terminology employed herein is for the purpose
of description and not of limitation. Therefore, while the embodiments herein have
been described in terms of red embodiments, those skilled in the art will
recognize that the embodiments herein can be practiced with modification within
the spirit and scope of the embodiments as described herein.
Claims (1)
- Claims: 1. A process for ing an extract of Momora’ica tia comprising the following steps: a) preparing crude juice from crushed and chopped unripe Momordz'ca tia fresh fruit to which water is added intermittently; b) filtering the crude juice to obtain filtered juice; 0) modifying the pH of the juice between 2.5 to 4 pH by adding an organic acid; d) allowing the pH modified juice to stabilize by allowing the pH added firltered~juice—toestandefor—S-toa-S-minut-es;* e) neutralizing the stabilized juice with the help of alkali; t) allowing the neutralized juice to stand for a period of 20 to 30 minutes; g) rechecking the pH level of the juice for neutralization; and h) drying the neutralized juice to obtain dried t of Momora’ica charantz'a. !Q A process as claimed in claim 1, wherein the organic acid is at least one ed from the group consisting of citric acid, acetic acid, lactic acid, tartaric acid and oxalic acid. A process as claimed in claim 1, wherein the organic acid is citric acid. A process claimed in claim 1, wherein the organic acid is lemon juice. The process as claimed in any one of the preceding claims in which the acidic pH is adjusted to a value of 3.8. 6. The process as. claimed in any one of the preceding claims in which the alkali used for neutralization is at least one alkali selected from the group consisting of sodium hydroxide, potassium ide, m hydroxide and sodium bicarbonate. 7. The process as claimed in any one of the ing claims, wherein the normality of the alkali used for neutralization is in the range of 0.1 Nto4N. 8. The process as claimed in any one of the preceding claims, wherein during the step of neutralization the alkali is added dropwise in the stabilized acidic juice. 9. The process as claimed in any one of the preceding claims, wherein the dried extract is obtained by treating the neutralized juice in at least one manner selected from the group consisting of spray drying, vacuum drying and freeze drying to obtain a dried extract of Momordica tia. 10. A formulation ning the dried extract of Momordica charantia prepared in accordance with any one of the claims in a dosage form selected from the group consisting of powder, granule, capsule, tablet, sachet, suspension, liquid, pastille, g gum, lozenges and pill.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN246/MUM/2011 | 2011-01-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ613666A true NZ613666A (en) | 2014-02-28 |
NZ613666B NZ613666B (en) | 2014-06-04 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101396458B1 (en) | A food or drink composition comprising fermented eastern prickly pear | |
CN105707874A (en) | Horseradish tree leaf tablets and preparation method thereof | |
CA2825845C (en) | Process for preparation of a herbal extract | |
WO2015063674A1 (en) | Herbal composition, process for its preparation and use thereof | |
JP2006036787A (en) | Xanthine oxidase inhibitor | |
KR101713309B1 (en) | Food composition or pharmaceutical composition for immune activity with the extract of Pinus Koraiensis peel | |
JP2024101600A (en) | Solid Composition | |
JP6122200B1 (en) | Anti-glycation composition | |
AU2012210142B2 (en) | Process for preparation of a herbal extract | |
NZ613666A (en) | Process for preparation of a herbal extract | |
NZ613666B (en) | Process for preparation of a herbal extract | |
CN109331093B (en) | Plant composition and application thereof | |
JP2005089374A (en) | Food and drink having function for preventing increase in blood glucose level | |
JP2016108265A (en) | Persistent antioxidant | |
JP2001046019A (en) | Nutritive composition originated from citrus fruit | |
KR20150018167A (en) | A pharmaceutical composition comprising fermented Eastern prickly pear | |
KR20170005873A (en) | Oral composition for improving systemic symptoms including sensitivity to cold | |
KR102007096B1 (en) | Composition for preventing or treating hearing loss comprising Viscum ovalifolium extracts | |
JPWO2020100917A1 (en) | Prophylactic and / or therapeutic agents for neurodegenerative diseases | |
JP2005053818A (en) | Trypsin inhibitor | |
CN111557957A (en) | Composition for oral administration comprising processed myrobalan and use of processed myrobalan | |
CN110433187A (en) | A kind of Turnip extractive is in preparation treatment, prevention or improves application and its preparation process in treatment parkinsonism | |
JPH08245408A (en) | Substance having analgesic activity | |
JP2009269895A (en) | Drug-induced liver disorder inhibitory composition | |
JP2006083146A (en) | Blood glucose level increase inhibitor |